BioSpace News Archive

Pixium Vision SA announces that it successfully negotiated a 3 million Euro convertible shareholders’ loan with Bpifrance and Sofinnova.

Surgalign Holdings, Inc. announced that following a competitive court-supervised marketing and sale process, including a competitive auction, the Company has selected Xtant Medical Holdings, Inc. as the successful bidder for its hardware and biologics assets and Augmedics, Inc. as the successful bidder for its digital health assets.

STRATA Skin Sciences, Inc., a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that it plans to release its second quarter 2023 financial results on Wednesday, August 9, 2023.

Chinook Therapeutics, Inc. today announced that the first patient with IgA nephropathy (IgAN) has been enrolled in the BEYOND study, a pivotal phase 3 clinical trial evaluating the safety and efficacy of zigakibart (BION-1301), a potentially disease-modifying anti-APRIL monoclonal antibody.

Semler Scientific, Inc. today announced that it will report financial results for the second quarter ended June 30, 2023 , after the close of U.S. financial markets on Thursday, August 10, 2023.

Alzheimer’s disease (AD) is the most common neurodegenerative disorder in the world, associated with symptoms like memory loss and cognitive impairment. Brain lesions caused by the aggregation of amyloid β (Aβ) and neurofibrillary tangles are believed to be the main cause of AD.

Ryan Huang, CEO of Beauty-Stem Biomedical, and Dr. David Chen, director of Diagnostic Medical Group of Southern California, delivered a compelling presentation highlighting the numerous benefits of CD34 stem cells.

LumeDEL LLC introduces the NewDEL™ Fiber-coupled LED sources that are designed to generate high radiant power with spectrally stable output and combining high performance

Navidea Biopharmaceuticals, Inc. received written notification from NYSE American LLC stating that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock of Navidea Biopharmaceuticals, Inc. — ticker symbol NAVB —from the Exchange.